BCRX · Biocryst Pharmaceuticals Inc
$8.33
+0.06 (+0.73%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$2.11B
Shares
255.54M
Volume · Sep 30
13.1M
Avg daily vol (3M)
4.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.33
Open$8.28
Day$8.18–8.42
52W close$6.24–11.11
Avg vol 30d4.6M
Short int34.9M · 13.6% float · 7.3d
Short vol20%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Oct 25, 2026
Est · unconfirmed
· in 3 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$940.61M
Trailing 12 months
Net income (TTM)
−$384.67M
Trailing 12 months
Revenue growth YoY
+33.6%
Year over year
Operating margin
-33.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
17.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$42.83M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20.6%
Year over year · more shares
Price change (1Y)
+9.5%
Trailing year
Short interest
13.6%
Latest settlement · 7.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−4%
below
Price vs 50-day avg
−10%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−16%
trailing
YTD return
+7%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +55 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.65% of float · ▲ +2.4% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
320 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
+381%
Y/Y
Free cash flow
$347.0M
Balance sheet
$206.2M
net cash
Quant / Vol
risk profile
Volatility
49%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Global net ORLADEYO revenue
· full year 2026
Initiated
$625M – $645M
Non-GAAP operating expenses
· full year 2026
Non-GAAP
Initiated
$420M – $440M
Guided vs delivered
· last 1 settled
Net revenues
full year 2021
guided $115M – $120M
$157.17M
Beat +33.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−4%
Neutral
Price vs 50-day avg
−10%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +55 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.65% of float · ▲ +2.4% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
320 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $8 · 43%
Range high $11
vs 200-day avg -4%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCRX
this stock
Biocryst Pharmaceuticals Inc
|
$2.11B | +6.8% | -4.4% | — | 13.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCRX | -2.8% | -16.0% | -15.8% | -14.1% | +6.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.1% | -16.1% | -27.9% | -13.5% | -5.1% |